A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

NCT07038876 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Placebo
DRUG: ML-007C-MA BID
DRUG: ML-007C-MA QD

Sponsor

MapLight Therapeutics